OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Pagel on Ongoing Research With BTK Inhibitors in CLL

May 6th 2020

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Naumann on Unanswered Questions With PARP Inhibitors in Ovarian Cancer

May 6th 2020

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses unanswered questions with PARP inhibitors in ovarian cancer.

Dr. Overman on Ongoing Research With Immunotherapy in Microsatellite Stable CRC

May 6th 2020

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Dr. Ocean on Combating the Emotional Toll Caused by COVID-19 in Cancer

May 6th 2020

Allyson Ocean, MD, discusses the emotional toll COVID-19 has had on patients and practitioners in the oncology space and the importance of self-care and social distancing.

Dr. Wang on Unique Properties of KTE-X19 in Relapsed/Refractory MCL

May 5th 2020

Michael Wang, MD, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma.

Dr. Wang-Gillam on Next Steps With Defactinib Combo in Pancreatic Ductal Adenocarcinoma

May 5th 2020

Andrea Wang-Gillam, MD, PhD, discusses potential next steps with a novel combination regimen in pancreatic ductal adenocarcinoma.

Dr. Oh on Challenges With Developing Novel Targeted Agents in Prostate Cancer

May 5th 2020

William K. Oh, MD, discusses challenges with developing novel targeted agents in prostate cancer.

Dr. Lopategui on the Evolution of Molecular Testing in NSCLC

May 5th 2020

Jean Lopategui, MD, discusses the evolution of molecular testing in non–small cell lung cancer.

Dr. Tolaney on Remaining Questions With CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

May 5th 2020

Sara M. Tolaney, MD, MPH, discusses remaining questions with CDK4/6 inhibitors in hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr. Coleman on Recent Advances and Remaining Questions in Ovarian Cancer

May 5th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses recent advances made in the treatment of patients with ovarian cancer and remaining questions regarding the role of immunotherapy.

Dr. Carbone on Acquired Resistance to Osimertinib in NSCLC

May 5th 2020

David P. Carbone, MD, PhD, discusses a study evaluating acquired resistance to osimertinib in non–small cell lung cancer.

Dr. Hwang on the Addition of Radium-223 to Abiraterone Acetate and Prednisone in mCRPC

May 5th 2020

Clara Hwang, MD, discusses the phase 3 ERA-223 trial evaluating the addition of radium-223 dichloride to abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer and bone metastases.

Dr. Williams on NLR as a Prognostic Biomarker in NSCLC

May 5th 2020

Terence M. Williams, MD, PhD, discusses research examining a serum biomarker, neutrophil-to-lymphocyte ratio, in non–small cell lung cancer.

Dr. Desai Sheds Light on COVID-19 Risk Among Patients With Cancer

May 5th 2020

Aakash Desai, MD, MPH, provides additional insight into his research on COVID-19 risk and patients with cancer and shed light on how institutions are taking action against the virus.

Dr. Favret on the Evolution of Treatment in HER2+ Breast Cancer

May 4th 2020

Anne Favret, MD, discusses the evolution of treatment in HER2-positive breast cancer.

Dr. Michaelis on the Role of Interferon in MPNs

May 4th 2020

Laura C. Michaelis, MD, discusses the role of interferon in myeloproliferative neoplasms.

Dr. Miklos on Anticipated Sequencing Challenges With KTE-X19 in MCL

May 4th 2020

David Miklos, MD, discusses anticipated sequencing challenges with the investigational CAR T-cell therapy KTE-X19 in mantle cell lymphoma.

Dr. Yee on the Role of Carfilzomib in Relapsed/Refractory Multiple Myeloma

May 4th 2020

Andrew Yee, MD, discusses the role of carfilzomib in relapsed/refractory multiple myeloma.

Dr. Saba on the Impact of COVID-19 on Telehealth in Head and Neck Cancer

May 4th 2020

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses the impact of the coronavirus disease 2019 (COVID-19) on telehealth in head and neck cancer.

Dr. Voorhees on the Effectiveness of Idecabtagene Vicleucel in Multiple Myeloma

May 2nd 2020

Peter Voorhees, MD, discusses the evolution of idecabtagene vicleucel (ide-cel; bb2121) in the phase 2 KarMMa study in relapsed/refractory multiple myeloma.